Apr 1, 2008
By:
Walter Armstrong
When it comes to developing novel therapies from the animal kingdom, it's mostly a game of pick your poison
|
Apr 1, 2008
By:
Walter Armstrong
The contamination of heparin in China cast the drugmaker, its US supplier, and FDA as indifferent and incompetent. Then the story took a very strange turn...
|
Roche has always gone its own way: investing in biologics, championing personalized medicine, and checking its ego at the door when doing deals. Now that the rest of Big Pharma has caught on, can a new generation of leaders keep the Swiss giant ahead of its time?
Mar 1, 2008
By:
Walter Armstrong
Roche has always gone its own way with biologics, deals, and new medicines. Now that the rest of industry has caught on, how can Roche stay ahead of its time?
|
Pharm Exec's second-annual Brand of the Year honor goes to Chantix, Pfizer's breakthrough treatment for nicotine addiction: inspired innovation from molecule to consumer
Feb 1, 2008
By:
Walter Armstrong
With Chantix, Pfizer combined inspired drug design with innovative customer-focused marketing to make the first real medical assault on nicotine addiction.
|
|
Nov 1, 2007
By:
Walter Armstrong
Approvable letters delay NDAs, cost pharma plenty, and are at an all-time high. Industry says FDA is gun-shy; the agency says it's business as usual. Who's right?
|
How could one little digital deletion build up such a head of steam? It's a question of trust.
Oct 1, 2007
By:
Walter Armstrong
Gotcha, Big Pharma! Sort of.... Not me, a guy named Jeffrey Light. The young founder and head of tiny DC-based nonprofit Patients not Patents hit the wires recently, charging that Abbott Laboratories had edited its entry in Wikipedia, the online everybody-can-play encyclopedia, trying to make itself look better. Using a brand-new online tool called the Wiki Scanner, which allows anyone to track the source of any change entered into any of Wikipedia's 2 million articles, Light discovered that at 4:38 P.M. on July 2, 2007, several edits to the article on Abbott were made from a computer at Abbott's Chicago office.
|
Sep 12, 2007
By:
Walter Armstrong
Two Internet superpowers are invading online consumer-health territory. What does it mean for pharma?
|
Gary Herman, head of the new experimental-medicine division, is teaching Merck's storied scientists to fail...faster
Sep 1, 2007
By:
Walter Armstrong, Marylyn Donahue
That was the collective vow sworn by Big Pharma last December following Pfizer's $1 billion–down–the–tubes withdrawal of the cholesterol compound they had touted as the most important drug of the decade. The question is, What's the right organizational construct to support innovation—or at least to stop Phase III failures?
|
When Merck KGaA and Serono merged last September, some said it was a shotgun wedding, while others called it a good fit. Now that the honeymoon is over, Pharm Exec takes the measure of the match.
Sep 1, 2007
By:
Walter Armstrong
It's testimony to the high anxiety—and hectic activity—in the industry that the merger of German chemicals-to-pharmaceuticals firm Merck KGaA and Swiss biotech Serono elicited only faint fanfare. Both family-owned drugmakers boast an illustrious heritage, but their union garnered none of the pomp and circumstance befitting a marriage of European royalty.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
